Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis-Reference-Cited by-同舟云学术

Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis

Published:2017-01-04 Issue:5 Volume:20 Page:464-473
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Chastek Benjamin¹,Becker Laura K.¹,Chen Chieh-I²,Mahajan Puneet³,Curtis Jeffrey R.⁴

Affiliation:

1. Optum, Eden Prairie, MN, USA;

2. Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA;

3. Sanofi, Bridgewater, NJ, USA;

4. University of Alabama at Birmingham, Birmingham, AL, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2016.1275653

Reference46 articles.

1. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

2. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

3. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

4. Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term sustainability of response to upadacitinib among patients with active rheumatoid arthritis refractory to biological treatments: results up to 5 years from SELECT-BEYOND;RMD Open;2024-07

2. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

3. Real‐World Treatment and Care Patterns in Patients With Rheumatoid Arthritis Initiating First‐Line Tumor Necrosis Factor Inhibitor Therapy in the United States;ACR Open Rheumatology;2024-01-14

4. Comparative effectiveness of TNF inhibitor vs IL-6 receptor inhibitor as monotherapy or combination therapy with methotrexate in biologic-experienced patients with rheumatoid arthritis: An analysis from the CorEvitas RA Registry;Clinical Rheumatology;2023-04-15

5. Management of patients with inflammatory rheumatic diseases after treatment failure with a first tumour necrosis factor inhibitor: A narrative review;Modern Rheumatology;2023-04-06